GCTK

Glucotrack, Inc. (GCTK) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Glucotrack, Inc. is a clinical-stage biotechnology company developing the Glucotrack Continuous Blood Glucose Monitor (CBGM), a fully implantable device designed to measure glucose directly from the blood. The company has not yet commercialized its product and remains dependent on external financing. As of August 14, 2025, there were 899,410 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss for the six months ended June 30, 2025, increased to $11.6 million from $7.4 million in the prior year period. This was driven by a $3.3 million expense related to the change in fair value of derivative liabilities and increased General and Administrative (G&A) expenses.
• Derivative Liability Reduction: Total liabilities decreased significantly from $18.9 million (Dec 31, 2024) to $3.3 million (June 30, 2025). This was primarily due to the cashless exchange of Series B warrants into common stock and the repurchase of Series A warrants, which reduced the derivative liability balance from $17.4 million to $5 thousand.
• Capital Raise: The company raised approximately $10.7 million in net proceeds through public offerings (ATM program and Registered Direct Offering) during the six-month period, significantly improving liquidity compared to the prior year.
• Stock Splits: The company executed two reverse stock splits in 2025 (1-for-20 in February and 1-for-60 in June). All share data and per-share metrics in this report have been retroactively adjusted.

Outlook, Risks, and Management Commentary

• Clinical Progress: The company completed a First-in-Human (FIH) short-term clinical study in Q1 2025, reporting a Mean Absolute Relative Difference (MARD) of 7.7% and no serious adverse events. Regulatory approval for a long-term clinical study outside the U.S. was obtained in Q2 2025, with enrollment expected to begin in Q3 2025. Discussions with the FDA for a U.S. Investigational Device Exemption (IDE) are underway, with a filing expected in Q4 2025.
• Liquidity and Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. While cash balances improved to $9.6 million, the company estimates it requires approximately $15.0 million to fund operations for the next 12 months. Continued operations depend on securing additional equity or debt financing.
• Internal Controls: The company disclosed that its disclosure controls and procedures are ineffective due to material weaknesses in internal control over financial reporting, specifically citing general IT controls, insufficient accounting personnel, and inadequate segregation of duties. Remediation efforts are ongoing.
• Unusual Items: A $95 thousand loss was recognized in Q2 2025 from the repurchase of Series A warrants. Additionally, a $3.3 million non-cash charge related to the change in fair value of derivative liabilities impacted the six-month net loss.

Investor Verification Checklist

• Capital Sufficiency: Verify the company's ability to raise the estimated $15 million needed for operations, given the "substantial doubt" going concern warning.
• Internal Control Remediation: Monitor progress on fixing material weaknesses in financial reporting and IT controls to ensure future financial data reliability.
• Clinical Milestones: Track the start of the long-term clinical trial enrollment in Q3 2025 and the timeline for the FDA IDE submission in Q4 2025.
• Derivative Liability Exposure: Confirm the remaining exposure to derivative liabilities (currently $5 thousand) and potential future volatility if warrant terms are not fully settled.
• Share Count Dilution: Review the impact of the recent reverse stock splits and warrant exchanges on the total share count and potential future dilution from remaining warrants.